



## MEETING ABSTRACTS

### A Multi-Center Double-Blind, Randomized, Controlled Trial (db-RCT) to Evaluate the Effectiveness and Safety of Co-Administered Traumeel<sup>®</sup> (Tr14) and Zeel<sup>®</sup> (Ze14) Intra-articular (IA) Injections Versus IA Placebo in Patients with Moderate-to-Severe Pain Associated with OA of the Knee

**Abstract Number:** 2896

**Session:** Osteoarthritis - Clinical Aspects II: Osteoarthritis Risk Factors and Therapies

**Keywords:** Clinical Response, Knee, RCT, clinical research and osteoarthritis

**Year:** 2014

**Carlos Lozada**<sup>1</sup>, Eve del Rio<sup>2</sup>, Donald Reitberg<sup>2</sup>, Robert Smith<sup>2</sup>, Charles Kahn<sup>3</sup> and Roland W. Moskowitz<sup>4</sup>,  
<sup>1</sup>Rheumatology, University of Miami Miller School of Medicine, Miami, FL, Miami, FL, <sup>2</sup>Clinical Research, Rio Pharmaceutical Services, LLC, Bridgewater, NJ, <sup>3</sup>South Florida Rheumatology, Hollywood, FL, <sup>4</sup>Div of Rheum/Dept of Medicine, University Hospitals Case Medical Center, Cleveland, OH

#### **Background/Purpose:**

Tr14 & Ze14 is a combination of dilute biological and mineral extracts administered IA for painful knee OA. In response to clinician impressions of positive outcomes, a db-RCT to assess efficacy and safety compared to IA saline was deployed in the US.


#### **Methods:**

Pts with moderate-to-severe chronic knee OA were randomized to 3 weekly IA injections of either Tr14 & Ze14 or saline by clinical investigators experienced with use of the IA injection route. The primary efficacy variable was change in knee pain from Baseline to End-of-Study (Week 17) as measured by the WOMAC OA Pain Subscale (Section A, 1-5) 100 mm VAS. Secondary measures included Total WOMAC and subscores for stiffness (B), and physical function (C), change in pain following a 50 ft walk (100 mm VAS), patient and physician global assessments. Clinical relevance was assessed by comparing proportions of patients with reductions from baseline in WOMAC A scores greater than a validated benchmark Minimal Clinically Important Difference (MCID). This was chosen as -32.6 mm (the most conservative value) based on a study of outpatients with knee or hip OA where WOMAC VAS MCIDs ranged from -7.9mm to -32.6mm [see reference 59 Tauback et al., *Ann Rheum Dis.* 2005; 64(1):29-33 in the description of the WOMAC index published by ACR]. Safety was assessed by monitoring of vital signs, physical examinations of the target knee, adverse events and concomitant medications.

#### **Results:**

232 patients were randomized and treated (All Tr14 & Ze14, n=119, All Placebo, n=113; Intention-to-Treat (ITT) Tr14 & Ze14, n=117, Placebo, n= 111). Treatment arms were well balanced across demographic and baseline characteristics. Tr14 & Ze14 did not discriminate for WOMAC A Pain as expected after only 1 of 3 injections on Day 8 (p=0.3715), but subsequently was significantly different (p<0.05) on Days 15, 43, 57, 71, 85 and 99 (primary

endpoint day), and approached significance on Day 29 ( $p=0.0686$ ). Logistic regressions showed the proportion of MCID responders was not significant on Day 8. As this was an expected finding, it served as a no-effect internal-model-validation. Tr14 & Ze14 was significantly different ( $p<0.05$ ) on all subsequent days except Day 29 (approached significance,  $p=0.0599$ , Figure 1). 50' walk pain was similarly discriminating as was the physician global assessment. Total WOMAC and subscores B&C were directionally consistent with WOMAC A. There were no related SAEs. AEs were generally mild and unrelated to treatment. Local knee-related AEs, lab assessments, ECGs and vital signs were unremarkable and similar between treatments.



**Conclusion:**

Tr14 & Ze14 provided statistically significant and clinically relevant pain relief on days 15 to 99 in comparison to placebo. In this double-blind, randomized, controlled trial, a biological/mineral multi-extract combination was shown to be a safe and effective treatment for pain in moderate-to-severe knee OA.

**Disclosure:**

C. Lozada, Rio Pharmaceutical Services, 5, Heel USA, 5; E. del Rio, Biologische Heilmittel Heel GmbH, 5; D. Reitberg, Rio Pharmaceutical Services, LLC, 5; R. Smith, Rio Pharmaceutical Services, LLC, 5; C. Kahn, Biologische Heilmittel Heel GmbH, 5; R. W. Moskowitz, Rio Pharmaceutical Services, LLC, 5, Heel USA, 5

**Disclaimer:**

These statements have not been reviewed by the Food and Drug Administration. They are supported by traditional homeopathic principles.